{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-104969","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.770770+00:00","generated_at":"2026-05-17T17:55:29.731850+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adicet Bio Q2 net loss $31.2M; discontinues ADI-270, cuts workforce 30%","bullets":["Net loss $31.2M ($0.34/sh) vs $29.9M ($0.33/sh) in Q2 2024; R&D spending rose to $28.4M.","Cash $125.0M as of June 30, 2025, down from $176.3M at year-end 2024; runway into Q4 2026.","Discontinued ADI-270 for ccRCC; workforce reduced ~30% to extend cash runway.","Prioritizing ADI-212 (PSMA, prostate cancer); IND filing expected Q1 2026, data 2H 2026.","Phase 1 ADI-001 autoimmune trial expanded to IIM, SPS, AAV; preliminary data expected 2H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-104969","json":"https://secwatch.observer/filing/0000950170-25-104969.json","markdown":"https://secwatch.observer/filing/0000950170-25-104969.md","text":"https://secwatch.observer/filing/0000950170-25-104969.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017025104969/0000950170-25-104969-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017025104969/acet-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:55:29.731850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}